Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDA With Dihydroartemisinin + Piperaquine for Reducing Malaria in Zambia
NCT02329301Completed
- Sponsor
- PATH
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dihydroartemisinin and piperaquine in malaria (3 arms), sponsored by PATH. Primary endpoints: Parasite prevalence during the high transmission season among children <6 years old at 12 months and P.falciparum infection incidence rate among individuals ≥3 months at 12 months. Started Sep 2014; status: completed.
02
Drugs
dihydroartemisininpiperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02329301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329301.